GlassScriptPhysician profile
Simmi Dhaliwal
NPI 1275638009
$2,483.35
in general payments reported to CMS, 2019-2025
32 companies · $479 in 2025
The $479 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $279 · 2021: $500 · 2022: $381 · 2023: $344 · 2024: $179 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $631.85 | 2019-2025 | Liletta |
| Sumitomo Pharma America, INC. | $174.90 | 2023-2025 | Myfembree |
| Pfizer INC. | $173.95 | 2020-2025 | |
| Myovant Sciences INC. | $148.39 | 2021-2022 | |
| Sage Therapeutics, LLC | $145.04 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $112.83 | 2023-2025 | Accrufer |
| Coopersurgical, INC. | $111.23 | 2020-2023 | Paragard T 380a |
| Mayne Pharma Commercial LLC | $109.58 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.91 | 2019-2025 | |
| Astellas Pharma US INC | $97.43 | 2023-2025 | Veozah |
| Organon LLC | $78.52 | 2021-2025 | Nexplanon |
| Therapeuticsmd, INC. | $64.32 | 2020-2021 | |
| Bard Access Systems, INC. | $56.54 | 2019 | |
| Convatec INC. | $49.28 | 2022 | |
| Exeltis, USA INC. | $49.02 | 2023-2025 | Slynd |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $46.12 | 2021-2022 | |
| Avanos Medical | $41.52 | 2022-2024 | On-Q* Pump and Accessories |
| Covidien LP | $33.20 | 2019 | |
| Medtronic, INC. | $25.42 | 2025 | Truclear |
| Amag Pharmaceuticals, INC. | $23.72 | 2019 | |
| Bard Peripheral Vascular, INC. | $21.56 | 2021 | |
| Allergan, INC. | $20.95 | 2020 | |
| Merck Sharp & Dohme LLC | $19.64 | 2019 | |
| Meditrina | $18.75 | 2025 | |
| Agile Therapeutics, INC. | $18.62 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $18.31 | 2023 | Exparel |
| Smith+Nephew, INC. | $17.98 | 2022 | |
| Ethicon US, LLC | $16.76 | 2019 | |
| Hologic Sales and Service, LLC | $16.33 | 2022 | |
| Minerva Surgical, INC | $14.61 | 2019 | |
| Medicem INC. | $13.16 | 2021 | |
| Avion Pharmaceuticals | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simmi Dhaliwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.